Protease-activated Receptor 1 Targeted Screening of Potential Antithrombotic Compounds with Hemostatic Activity from Polygonum Amplexicaule D. Don var. Sinense Forb
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-025-07797-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Shiyi Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hunan University of Chinese Medicine, 300 Bachelors Road, Yuelu District, Changsha Hunan, 410208, China. Hauptthemen laut MEDLINE: Polygonum, Fibrinolytic Agents, Receptor, PAR-1, Platelet Aggregation Inhibitors. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation Project, Hunan Provincial Scientific Research Project of Traditional Chinese Medicine, Scientific Research Fund of Hunan Provincial Education Department.
Abstract (Originalsprache)
PURPOSE: this study aims to screen Protease-activated receptor 1 (PAR1) inhibitory active components with low bleeding side effects from anti-thrombin phytochemicals in Polygonum amplexicaule D. Don var. sinense Forb (PAF) to achieve multi-pathway antithrombosis without disrupting platelet hemostasis. METHODS: Docking simulation and platelet aggregation test were used to investigate interaction of PAR1-ligands to screen out anti-PAR1 active ingredients. FeCl3-induced carotid artery (CA) thrombosis and inferior vena cava (IVC)-ligated thrombosis model were constructed to collect thrombi to weigh. Histopathological analysis, coagulation function, and hemorheological indicator detection of administered rats were conducted to analyze antithrombotic effectiveness and mechanism of these compounds, which were injected in tail veins of mice to evaluate bleeding side effects. RESULTS: Three promising ligands (epigallocatechin gallate, homoorientin, and myricetin) with strong affinity of PAR1 were selected from PAF. Epigallocatechin gallate and homoorientin showed antithrombotic effects with decreased bleeding tendency based on activity validation, suggesting that they may be prospective and effective candidate compounds of PAR1 antagonists. CONCLUSION: the integrative strategy applied to these active components allowed to rapidly discover compounds with reducing bleeding side effects during thrombus treatment, providing valuable references for precisely targeted therapy and mechanism exploration of medicinal plants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hunan University of Chinese Medicine, 300 Bachelors Road, Yuelu District, Changsha Hunan, 410208, China.
- Science & Technology Innovation Center, Hunan University of Chinese Medicine, 300 Bachelors Road, Yuelu District, Changsha Hunan, 410208, China. zhaohongq@hnucm.edu.cn.
- School of Pharmacy, Hunan University of Chinese Medicine, 300 Bachelors Road, Yuelu District, Changsha Hunan, 410208, China. 1052262329@qq.com.
ORCID-Profile: Guangming Xu
Förderung
- Hunan Provincial Natural Science Foundation Project
- Hunan Provincial Scientific Research Project of Traditional Chinese Medicine
- Scientific Research Fund of Hunan Provincial Education Department
Zitieren
APA
Huang, S., He, X., Dai, J., Zou, T., Zhao, H., & Xu, G. (2025). Protease-activated Receptor 1 Targeted Screening of Potential Antithrombotic Compounds with Hemostatic Activity from Polygonum Amplexicaule D. Don var. Sinense Forb. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-025-07797-9
Vancouver
Huang S, He X, Dai J, Zou T, Zhao H, Xu G. Protease-activated Receptor 1 Targeted Screening of Potential Antithrombotic Compounds with Hemostatic Activity from Polygonum Amplexicaule D. Don var. Sinense Forb. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-025-07797-9
BibTeX
@article{Huang2025,
author = {Huang, Shiyi and He, Xiangchang and Dai, Jie and Zou, Ting and Zhao, Hongqing and Xu, Guangming},
title = {Protease-activated Receptor 1 Targeted Screening of Potential Antithrombotic Compounds with Hemostatic Activity from Polygonum Amplexicaule D. Don var. Sinense Forb},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-025-07797-9}
}
EUVIMED